Exact Mass: 433.1317

Exact Mass Matches: 433.1317

Found 39 metabolites which its exact mass value is equals to given mass value 433.1317, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

N-acetylaspartylglutamylglutamic acid

N-Acetylaspartylglutamylglutamate; N-Acetyl-L-aspartyl-L-glutamyl-L-glutamate; NAAG2

C16H23N3O11 (433.1333)


   

Dihydrozeatin riboside monophosphate

Dihydrozeatin riboside monophosphate

C15H24N5O8P (433.1362)


   

Tolmetin glucuronide

(2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-({2-[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetyl}oxy)oxane-2-carboxylic acid

C21H23NO9 (433.1373)


Tolmetin glucuronide belongs to the family of Glucuronic Acid Derivatives. These are compounds containing a glucuronic acid moeity (or a derivative), which consists of a glucose moiety with the C6 carbon oxidized to a carboxylic acid.

   

4-Hydroxy-5-[3-(sulfooxy)phenyl]pentanoylcarnitine

3-({4-hydroxy-5-[3-(sulfooxy)phenyl]pentanoyl}oxy)-4-(trimethylazaniumyl)butanoate

C18H27NO9S (433.1406)


4-hydroxy-5-[3-(sulfooxy)phenyl]pentanoylcarnitine is an acylcarnitine. More specifically, it is an 4-hydroxy-5-[3-(sulfooxy)phenyl]pentanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-hydroxy-5-[3-(sulfooxy)phenyl]pentanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-hydroxy-5-[3-(sulfooxy)phenyl]pentanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Amustaline

(N,N-Bis(2-chloroethyl))-2-aminoethyl-3-((acridin-9-yl)amino)propionate

C22H25Cl2N3O2 (433.1324)


D000970 - Antineoplastic Agents > D018906 - Antineoplastic Agents, Alkylating > D009588 - Nitrogen Mustard Compounds C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent

   

7-[(Gly-L-Phe-)Amino]-4-(trifluoromethyl)-2H-1-benzopyran-2-one

2-(2-aminoacetamido)-N-[2-oxo-4-(trifluoromethyl)-2H-chromen-7-yl]-3-phenylpropanamide

C21H18F3N3O4 (433.1249)


   

2-[(Acridin-9-ylamino)methyl]-4-[bis(2-chloroethyl)amino]butanoic acid

4-[Bis(2-chloroethyl)amino]-2-{[(9,10-dihydroacridin-9-ylidene)amino]methyl}butanoate

C22H25Cl2N3O2 (433.1324)


   
   
   

Dihydrozeatin riboside-5-monophosphate

Dihydrozeatin riboside-5-monophosphate

C15H24N5O8P (433.1362)


   
   

Dihydrozeatin riboside-5-monophosphate sodium salt

Dihydrozeatin riboside-5-monophosphate sodium salt

C15H24N5O8P (433.1362)


   

Mefenamic acid Metabolite (b-D-Glucopyranuronic acid, 1-[2-[[3-(hydroxymethyl)-2-methylphenyl]amino]

Mefenamic acid Metabolite (b-D-Glucopyranuronic acid, 1-[2-[[3-(hydroxymethyl)-2-methylphenyl]amino]

C21H23NO9 (433.1373)


   

Tolmetin glucuronide

(2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[(2-{1-methyl-5-[(4-methylphenyl)carbonyl]-1H-pyrrol-2-yl}acetyl)oxy]oxane-2-carboxylic acid

C21H23NO9 (433.1373)


   

3-[p-[(2-chloro-4-nitrophenyl)azo]-N-phenethylanilino]propiononitrile

3-[p-[(2-chloro-4-nitrophenyl)azo]-N-phenethylanilino]propiononitrile

C23H20ClN5O2 (433.1305)


   

Pyrrolidinium,1,1-diethyl-3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-, bromide (1:1)

Pyrrolidinium,1,1-diethyl-3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-, bromide (1:1)

C22H28BrNO3 (433.1252)


   

9-(4-bromophenyl)-3,6-di-tert-butyl-9H-carbazole

9-(4-bromophenyl)-3,6-di-tert-butyl-9H-carbazole

C26H28BrN (433.1405)


   

(R)-N-Fmoc-3-amino-4-(phenylthio)butanoic Acid

(R)-N-Fmoc-3-amino-4-(phenylthio)butanoic Acid

C25H23NO4S (433.1348)


   

Fmoc-Cys(Bzl)-OH

Fmoc-Cys(Bzl)-OH

C25H23NO4S (433.1348)


   

Pipenzolate Bromide

Pipenzolate Bromide

C22H28BrNO3 (433.1252)


C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent

   

ALS-8176

Lumicitabine

C18H25ClFN3O6 (433.1416)


C471 - Enzyme Inhibitor > C25995 - RNA Polymerase Inhibitor

   

8-(2-Chloro-3,4,5-trimethoxy-benzyl)-2-fluoro-9-pent-4-ylnyl-9H-purin-6-ylamine

8-(2-Chloro-3,4,5-trimethoxy-benzyl)-2-fluoro-9-pent-4-ylnyl-9H-purin-6-ylamine

C20H21ClFN5O3 (433.1317)


   

[[N-(2,5-Diamino-6-hydroxy-pyrimidin-4-YL)-ureayl]-phen-4-YL]-carbonyl-glutamic acid

[[N-(2,5-Diamino-6-hydroxy-pyrimidin-4-YL)-ureayl]-phen-4-YL]-carbonyl-glutamic acid

C17H19N7O7 (433.1346)


   

4-Hydroxy-5-[3-(sulfooxy)phenyl]pentanoylcarnitine

4-Hydroxy-5-[3-(sulfooxy)phenyl]pentanoylcarnitine

C18H27NO9S (433.1406)


   

2-[4-[(4-Chlorophenyl)methoxy]phenyl]-5-[3-(1-imidazolyl)propylamino]-4-oxazolecarbonitrile

2-[4-[(4-Chlorophenyl)methoxy]phenyl]-5-[3-(1-imidazolyl)propylamino]-4-oxazolecarbonitrile

C23H20ClN5O2 (433.1305)


   

bulbisine Trifluoroacetic acid

bulbisine Trifluoroacetic acid

C19H22F3NO7 (433.1348)


A natural product found in Crinum asiaticum var. sinicum.

   

3-[2-[(1,5-Dimethyl-3-oxo-2-phenyl-4-pyrazolyl)amino]-2-oxoethyl]-4-oxo-1-phthalazinecarboxylic acid

3-[2-[(1,5-Dimethyl-3-oxo-2-phenyl-4-pyrazolyl)amino]-2-oxoethyl]-4-oxo-1-phthalazinecarboxylic acid

C22H19N5O5 (433.1386)


   

5-Ethyl-2-[[[3-(4-morpholinyl)-4-nitrophenyl]-oxomethyl]amino]-3-thiophenecarboxylic acid ethyl ester

5-Ethyl-2-[[[3-(4-morpholinyl)-4-nitrophenyl]-oxomethyl]amino]-3-thiophenecarboxylic acid ethyl ester

C20H23N3O6S (433.1307)


   

2-(4-chlorophenoxy)-N-[3-(dimethylamino)propyl]-N-(4-methoxy-1,3-benzothiazol-2-yl)acetamide

2-(4-chlorophenoxy)-N-[3-(dimethylamino)propyl]-N-(4-methoxy-1,3-benzothiazol-2-yl)acetamide

C21H24ClN3O3S (433.1227)


   

4-[4-[(1S,5R)-3-(4-fluorophenyl)sulfonyl-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]benzonitrile

4-[4-[(1S,5R)-3-(4-fluorophenyl)sulfonyl-3,6-diazabicyclo[3.1.1]heptan-7-yl]phenyl]benzonitrile

C24H20FN3O2S (433.126)


   

BAY-545

BAY-545

C18H22F3N3O4S (433.1283)


BAY-545 is a potent and selective A2B adenosine receptor antagonist, with an IC50 of 59 nM. BAY-545 also exhibits IC50s of 66, 400, 280 nM for human, mouse, rat A2B adenosine receptor in cells, respectively, and a Ki of 97 nM for human A2B adenosine receptor, with more selectivity over A1, A2A, and A3 adenosine receptor[1].

   

[(2r,3r,4r,5s)-3,4-dihydroxy-5-(6-{[(3s)-4-hydroxy-3-methylbutyl]amino}purin-9-yl)oxolan-2-yl]methoxyphosphonic acid

[(2r,3r,4r,5s)-3,4-dihydroxy-5-(6-{[(3s)-4-hydroxy-3-methylbutyl]amino}purin-9-yl)oxolan-2-yl]methoxyphosphonic acid

C15H24N5O8P (433.1362)


   

4,11,14-trihydroxy-15-(1h-indol-3-yl)-13-oxa-2,9-diazatetracyclo[8.7.0.0³,⁸.0¹²,¹⁶]heptadeca-1,3,5,7,9-pentaene-14-carboxylic acid

4,11,14-trihydroxy-15-(1h-indol-3-yl)-13-oxa-2,9-diazatetracyclo[8.7.0.0³,⁸.0¹²,¹⁶]heptadeca-1,3,5,7,9-pentaene-14-carboxylic acid

C23H19N3O6 (433.1274)


   

(11r,12r,15s,16s)-4,11,14-trihydroxy-15-(1h-indol-3-yl)-13-oxa-2,9-diazatetracyclo[8.7.0.0³,⁸.0¹²,¹⁶]heptadeca-1,3,5,7,9-pentaene-14-carboxylic acid

(11r,12r,15s,16s)-4,11,14-trihydroxy-15-(1h-indol-3-yl)-13-oxa-2,9-diazatetracyclo[8.7.0.0³,⁸.0¹²,¹⁶]heptadeca-1,3,5,7,9-pentaene-14-carboxylic acid

C23H19N3O6 (433.1274)


   

n-{5,5-dichloro-4-methyl-1-oxo-1-[2-(1,3-thiazol-2-yl)pyrrolidin-1-yl]pentan-2-yl}-n,3-dimethylbutanamide

n-{5,5-dichloro-4-methyl-1-oxo-1-[2-(1,3-thiazol-2-yl)pyrrolidin-1-yl]pentan-2-yl}-n,3-dimethylbutanamide

C19H29Cl2N3O2S (433.1357)


   

methyl (9s)-14-chloro-4,5,15,16-tetramethoxy-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2,4,6,13,15-hexaene-10-carboxylate

methyl (9s)-14-chloro-4,5,15,16-tetramethoxy-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2,4,6,13,15-hexaene-10-carboxylate

C22H24ClNO6 (433.1292)


   

(11s,12r,15s,16s)-4,11,14-trihydroxy-15-(1h-indol-3-yl)-13-oxa-2,9-diazatetracyclo[8.7.0.0³,⁸.0¹²,¹⁶]heptadeca-1,3,5,7,9-pentaene-14-carboxylic acid

(11s,12r,15s,16s)-4,11,14-trihydroxy-15-(1h-indol-3-yl)-13-oxa-2,9-diazatetracyclo[8.7.0.0³,⁸.0¹²,¹⁶]heptadeca-1,3,5,7,9-pentaene-14-carboxylic acid

C23H19N3O6 (433.1274)


   

4,4-dichloro-n,3-dimethyl-n-{4-methyl-1-oxo-1-[2-(1,3-thiazol-2-yl)pyrrolidin-1-yl]pentan-2-yl}butanamide

4,4-dichloro-n,3-dimethyl-n-{4-methyl-1-oxo-1-[2-(1,3-thiazol-2-yl)pyrrolidin-1-yl]pentan-2-yl}butanamide

C19H29Cl2N3O2S (433.1357)


   

methyl 14-chloro-4,5,15,16-tetramethoxy-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2,4,6,13,15-hexaene-10-carboxylate

methyl 14-chloro-4,5,15,16-tetramethoxy-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2,4,6,13,15-hexaene-10-carboxylate

C22H24ClNO6 (433.1292)